A point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Chen, Jeffrey M ^a   Uplekar, Swapna ^a   Gordon, Stephen V ^b   Cole, Stewart T ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; CYCLOSERINE; PROTEIN CYCA; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CONTROLLED STUDY; CYCA GENE; GENE IDENTIFICATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRAIN DIFFERENCE; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; BASE SEQUENCE; BCG VACCINE; CYCLOSERINE; DRUG RESISTANCE, BACTERIAL; GENE KNOCK-IN TECHNIQUES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, SECONDARY; SEQUENCE HOMOLOGY, AMINO ACID; SYMPORTERS;

EID: 84865074267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043467     Document Type: Article

References (36)

1. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, et al. ((2007)) Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 104:: 5596--5601.
2. Mostowy S, Tsolaki AG, Small PM, Behr MA, ((2003)) The in vitro evolution of BCG vaccines. Vaccine 21:: 4270--4274.
3. Chen JM, Islam ST, Ren H, Liu J, ((2007)) Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine 25:: 8114--8122.
4. Leung AS, Tran V, Wu Z, Yu X, Alexander DC, et al. ((2008)) Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genomics 9:: 413.
5. Behr MA, Wilson MA, Gill WP, Salamon H, ((1999)) Schoolnik GK, et al ((1999)) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:: 1520--1523.
6. Garcia-Pelayo MC, Uplekar S, Keniry A, Mendoza Lopez P, Garnier T, et al. ((2009)) A comprehensive survey of single nucleotide polymorphisms (SNPs) across Mycobacterium bovis strains and M. bovis BCG vaccine strains refines the genealogy and defines a minimal set of SNPs that separate virulent M. bovis strains and M. bovis BCG strains. Infect Immun 77:: 2230--2238.
7. Pym AS, Brodin P, Brosch R, Huerre M, Cole ST, ((2002)) Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 46:: 709--717.
8. TB-Alliance ((2008)) Handbook of anti-tuberculosis agents. Cycloserine. Tuberculosis (Edinb) 88:: 100--101.
9. Caminero JA, Sotgiu G, Zumla A, Migliori GB, ((2010)) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10:: 621--629.
10. Goh KS, Rastogi N, ((1991)) Rapid preliminary differentiation of species within the Mycobacterium tuberculosis complex: proposition of a radiometric method. Res Microbiol 142:: 659--665.
11. Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC, ((2010)) Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob Agents Chemother 55:: 291--301.
12. Halouska S, Chacon O, Fenton RJ, Zinniel DK, Barletta RG, et al. ((2007)) Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: role of D-alanine racemase. J Proteome Res 6:: 4608--4614.
13. Caceres NE, Harris NB, Wellehan JF, Feng Z, Kapur V, et al. ((1997)) Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J Bacteriol 179:: 5046--5055.
14. Feng Z, Barletta RG, ((2003)) Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob Agents Chemother 47:: 283--291.
15. Belanger AE, Porter JC, Hatfull GF, ((2000)) Genetic analysis of peptidoglycan biosynthesis in mycobacteria: characterization of a ddlA mutant of Mycobacterium smegmatis. J Bacteriol 182:: 6854--6856.
16. Chacon O, Feng Z, Harris NB, Caceres NE, Adams LG, et al. ((2002)) Mycobacterium smegmatis D-Alanine Racemase Mutants Are Not Dependent on D-Alanine for Growth. Antimicrob Agents Chemother 46:: 47--54.
17. Sassetti CM, Boyd DH, Rubin EJ, ((2003)) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48:: 77--84.
18. Saier MH Jr, Yen MR, Noto K, Tamang DG, Elkan C, ((2009)) The Transporter Classification Database: recent advances. Nucleic Acids Res 37:: D274--278.
19. David HL, ((1971)) Resistance to D-cycloserine in the tubercle bacilli: mutation rate and transport of alanine in parental cells and drug-resistant mutants. Appl Microbiol 21:: 888--892.
20. Feher T, Cseh B, Umenhoffer K, Karcagi I, Posfai G, ((2006)) Characterization of cycA mutants of Escherichia coli. An assay for measuring in vivo mutation rates. Mutat Res 595:: 184--190.
21. Tusnady GE, Simon I, ((2001)) The HMMTOP transmembrane topology prediction server. Bioinformatics 17:: 849--850.
22. Durek C, Rusch-Gerdes S, Jocham D, Bohle A, ((2000)) Sensitivity of BCG to modern antibiotics. Eur Urol 37 Suppl 1: 21--25.
23. Danilchanka O, Mailaender C, Niederweis M, ((2008)) Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob Agents Chemother 52:: 2503--2511.
24. Siroy A, Mailaender C, Harder D, Koerber S, Wolschendorf F, et al. ((2008)) Rv1698 of Mycobacterium tuberculosis represents a new class of channel-forming outer membrane proteins. J Biol Chem 283:: 17827--17837.
25. Wang F, Jain P, Gulten G, Liu Z, Feng Y, et al. ((2010)) Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob Agents Chemother 54:: 3776--3782.
26. Peteroy M, Severin A, Zhao F, Rosner D, Lopatin U, et al. ((2000)) Characterization of a Mycobacterium smegmatis mutant that is simultaneously resistant to D-cycloserine and vancomycin. Antimicrob Agents Chemother 44:: 1701--1704.
27. Chen JM, Alexander DC, Behr MA, Liu J, ((2003)) Mycobacterium bovis BCG vaccines exhibit defects in alanine and serine catabolism. Infect Immun 71:: 708--716.
28. Bange FC, Collins FM, Jacobs WR Jr, ((1999)) Survival of mice infected with Mycobacterium smegmatis containing large DNA fragments from Mycobacterium tuberculosis. Tuber Lung Dis 79:: 171--180.
29. Wards BJ, Collins DM, ((1996)) Electroporation at elevated temperatures substantially improves transformation efficiency of slow-growing mycobacteria. FEMS Microbiol Lett 145:: 101--105.
30. Donnelly-Wu MK, Jacobs WR Jr, Hatfull GF, ((1993)) Superinfection immunity of mycobacteriophage L5: applications for genetic transformation of mycobacteria. Mol Microbiol 7:: 407--417.
31. Griffith ME, Bodily HL, ((1992)) Stability of antimycobacterial drugs in susceptibility testing. Antimicrob Agents Chemother 36:: 2398--2402.
32. Lew JM, Kapopoulou A, Jones LM, Cole ST, ((2010)) TubercuList- 10 years after. Tuberculosis (Edinb) 91:: 1--7.
33. Corpet F, ((1988)) Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16:: 10881--10890.
34. Bryson K, McGuffin LJ, Marsden RL, Ward JJ, Sodhi JS, et al. ((2005)) Protein structure prediction servers at University College London. Nucleic Acids Res 33:: W36--38.
35. Spyropoulos IC, Liakopoulos TD, Bagos PG, Hamodrakas SJ, ((2004)) TMRPres2D: high quality visual representation of transmembrane protein models. Bioinformatics 20:: 3258--3260.
36. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. ((1998)) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:: 537--544.